Korsana Biosciences, Inc. (KRSA)
37.56
+2.11
(+5.95%)
USD |
NASDAQ |
Nov 20, 16:00
37.33
-0.23
(-0.61%)
After-Hours: 20:00
Korsana Biosciences Research and Development Expense (TTM) : 43.39M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 43.39M |
| June 30, 2026 | 21.73M |
| March 31, 2026 | 21.78M |
| December 31, 2025 | 21.09M |
| September 30, 2025 | 20.63M |
| June 30, 2025 | 0.229M |
| March 31, 2025 | 0.278M |
| December 31, 2024 | 0.286M |
| September 30, 2024 | 0.254M |
| June 30, 2024 | 0.753M |
| March 31, 2024 | 0.987M |
| December 31, 2023 | 1.515M |
| September 30, 2023 | 2.667M |
| June 30, 2023 | 3.501M |
| March 31, 2023 | 13.38M |
| December 31, 2022 | 22.55M |
| September 30, 2022 | 31.83M |
| Date | Value |
|---|---|
| June 30, 2022 | 37.45M |
| March 31, 2022 | 39.29M |
| December 31, 2021 | 37.64M |
| September 30, 2021 | 39.27M |
| June 30, 2021 | 45.94M |
| March 31, 2021 | 47.68M |
| December 31, 2020 | 56.41M |
| September 30, 2020 | 65.00M |
| June 30, 2020 | 73.60M |
| March 31, 2020 | 85.56M |
| December 31, 2019 | 94.66M |
| September 30, 2019 | 96.43M |
| June 30, 2019 | 95.63M |
| March 31, 2019 | 92.13M |
| December 31, 2018 | 87.72M |
| September 30, 2018 | 89.63M |
| June 30, 2018 | 88.97M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Q32 Bio, Inc. | 15.94M |
| IRulya Therapeutics, Inc. | 30.76M |
| Climb Bio, Inc. | 43.60M |
| PepGen Inc. | 52.70M |
| Bridgebio Oncology Therapeutics, Inc. | 156.69M |